Patents Examined by Sagar Patel
  • Patent number: 10435369
    Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
  • Patent number: 10428030
    Abstract: The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognitive disorders and/or memory deficits, as well as chronic and acute pain and other related CNS disorders.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: October 1, 2019
    Assignee: Trillium Therapeutics
    Inventor: Abdelmalik Slassi
  • Patent number: 10421716
    Abstract: The invention relates to a novel process for preparing ?-carboxamide pyrrolidine derivatives, in particular (2S, 5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide, and to novel intermediates for use in said process along with processes for preparing said intermediates.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: September 24, 2019
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: David MacPherson, David Witty, Gerard Giblin, Michael Williams, Donald Walker, William Kiesman, Tamera Mack
  • Patent number: 10406167
    Abstract: The present disclosure relates platinum(IV) and texaphyrin linked conjugates and compositions comprising a texaphyrin and a platinum(IV) agent. The present disclosure also provides pharmaceutical compositions of the conjugates and compositions. Also, provided herein are methods of using the instant compounds in the treatment of cancer such as a platinum resistant cancer.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 10, 2019
    Inventors: Jonathan L. Sessler, Jonathan Arambula, Zahid H. Siddik, Gregory Thiabaud
  • Patent number: 10399972
    Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David J. Witter, Tesfaye Biftu, Purakkattle Biju, Stephane L. Bogen, Qingmei Hong, Chunhui Huang, Xianhai Huang, Bing Li, Min K. Park, David L. Sloman
  • Patent number: 10392351
    Abstract: Disclosed in the present invention is a method for preparing nilotinib intermediate 3-(4-methyl-1H-imidazol-1-yl)-5trifluoromethyl phenylamine (I). The method comprises the following steps: taking trifluorotoluene as an initial material, and preparing the nilotinib intermediate (I) by nitration, bromization, condensation and reduction successively Compared with the prior art, the preparation method has the following advantages: a relatively high yield, the raw materials are easily obtained, a concise process and few side reactions, and is adapted to industrial production, so the development of an economic technology of the bulk drug is promoted.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: August 27, 2019
    Inventors: Xuenong Xu, Deli Zeng, Liang Shu, Qing Zhang, Zhijian Bao, Jia Xue, Jian Su, Zhe Wang, Wenjie Zhou, Lingling Xie
  • Patent number: 10391182
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Patent number: 10369150
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 6, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10364220
    Abstract: The present invention relates to the synthesis of succinimides, in particular to a method for the synthesis of a succinimide compound, comprising the step of reacting an alkyne, with carbon monoxide and ammonia or an amine, in the presence of an iron catalyst, wherein the reaction is carried out in an amine liquid phase and/or in the absence of an ether solvent. The succinimides may be reduced to quaternary ammonium cations which may be used as structure directing agents in the synthesis of molecular sieves.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 30, 2019
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Kirk D. Schmitt, Stephen Zushma, Allen W. Burton
  • Patent number: 10328027
    Abstract: A new scalable process to control the particle size and the particle size distribution, comprising 5 steps: (i) suspension preparation in a mixture of solvents in which the API and/or excipient is partially soluble in one of the solvents; (ii) particle size reduction of the suspension; (iii) aging; (iv) stopping the aging by solvent removal; and (v) optionally, a step of isolating the processed ingredients in the form of powder.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: June 25, 2019
    Assignee: Hovione International Ltd.
    Inventors: Eunice Costa, Marcio Temtem, Luis Sobral, Constanca Cacela, Peter Villax
  • Patent number: 10323030
    Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: June 18, 2019
    Assignee: Syngenta Participations AG
    Inventors: Ottmar Franz Hueter, Andrew Edmunds, Andre Jeanguenat, Pierre Joseph Marcel Jung, Anke Buchholz, Michel Muehlebach
  • Patent number: 10308606
    Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for a method for synthesizing a compound of the formula:
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 4, 2019
    Assignee: On Target Laboratories, LLC
    Inventors: Sumith A. Kularatne, Pravin Gagare
  • Patent number: 10301323
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 28, 2019
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Patent number: 10301253
    Abstract: Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 28, 2019
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Martin Duplessis, Victor S. Gehling, Andrew Charles Good, Jean-Christophe Harmange, Yves LeBlanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Patent number: 10301264
    Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 28, 2019
    Assignee: The University of Nottingham
    Inventors: Steven James Harper, David Owen Bates, Melissa Gammons, Jonathan Morris
  • Patent number: 10294208
    Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: May 21, 2019
    Inventor: Helmut Schickaneder
  • Patent number: 10292968
    Abstract: The present application relates to substituted heterocycles compound of Formula I and pharmaceutical compositions thereof useful for the inhibition of BET protein function by binding to bromodomains (Formula I).
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 21, 2019
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Samuel David Brown, Craig Alan Coburn, Olesya Kharenko
  • Patent number: 10279044
    Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3?, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.
    Type: Grant
    Filed: May 29, 2016
    Date of Patent: May 7, 2019
    Assignees: Purdue Research Foundation, University of Utah Research Foundation
    Inventors: Stewart Andrew Low, Philip S. Low, Christopher Galliford, Jindrich Kopecek, Jiyan Yang
  • Patent number: 10273227
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 30, 2019
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith
  • Patent number: 10266499
    Abstract: The present invention relates to a compound of formula (I): wherein R1 is R3—IPU and R2 is the acyloxy residue of diclofenac, and specified by the following structures: wherein OH—R3—IPU is selected from and R4 and R5 may be the same or different selected from H and CH3 and salts, solvates and hydrates thereof.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 23, 2019
    Inventor: Claus Selch Larsen